1. Home
  2. ORMP vs ADAG Comparison

ORMP vs ADAG Comparison

Compare ORMP & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oramed Pharmaceuticals Inc.

ORMP

Oramed Pharmaceuticals Inc.

HOLD

Current Price

$2.88

Market Cap

104.6M

Sector

Health Care

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$1.84

Market Cap

84.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORMP
ADAG
Founded
2002
2011
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.6M
84.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ORMP
ADAG
Price
$2.88
$1.84
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.00
AVG Volume (30 Days)
226.0K
79.5K
Earning Date
11-13-2025
08-12-2025
Dividend Yield
N/A
N/A
EPS Growth
838.25
N/A
EPS
1.03
N/A
Revenue
$2,000,000.00
$103,204.00
Revenue This Year
N/A
$6,983.06
Revenue Next Year
N/A
$36.05
P/E Ratio
$2.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.82
$1.30
52 Week High
$3.20
$3.16

Technical Indicators

Market Signals
Indicator
ORMP
ADAG
Relative Strength Index (RSI) 59.49 48.90
Support Level $2.66 $1.61
Resistance Level $3.19 $1.92
Average True Range (ATR) 0.14 0.14
MACD 0.00 -0.01
Stochastic Oscillator 46.30 51.06

Price Performance

Historical Comparison
ORMP
ADAG

About ORMP Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

Share on Social Networks: